Like the competing product sodium stibogluconate, meglumine antimonate is a pentavalent antimony compound. Both substances are included in the WHO list of essential medicines. Meglumine antimonate has a molecular weight of 365.98.
Megluminantimonate
DefinitionThis section has been translated automatically.
IndicationThis section has been translated automatically.
Dosage and method of useThis section has been translated automatically.
Remember! Maximum dose 850 mg/day!
- Visceral Leishmaniasis: 20 mg/kg bw/day for at least 20 days (until no more parasites can be detected).
- Cutaneous leishmaniasis (except L. aethiopica, brasiliensis, guyanamensis):
- Local therapy: Injection of 1-3 ml under the ulcer, possibly 1-2 scds at intervals of 1-2 days.
- Systemic: 10-20 mg/kg bw/day until the smears are negative and then another 3 days.
- Cutaneous leishmaniasis (L. brasiliensis): 20 mg/kg bw/day until the lesion is healed (max. 4 weeks).
- Mucocutaneous leishmaniasis: 20 mg/kg bw/day until the smear is negative (max. 4 weeks).
- Diffuse cutaneous leishmaniasis: 20 mg/kg bw/day until clinical improvement occurs (usually for months).
PreparationsThis section has been translated automatically.
Glucantime (available through the international pharmacy).
LiteratureThis section has been translated automatically.
- Fernandez-Flores A et al. (2015) Morphological and immunohistochemical clues for the diagnosis of cutaneous leishmaniasis and the interpretation of CD1a status. J Am Acad Dermatol doi: 10.1016/j.jaad.2015.09.038
- Fischer T et al. (2024)Treatment of mucocutaneous leishmaniasis- a systematic review. JDDG 22:763-774
- Handler MZ et al. (2015) Cutaneous and mucocutaneous leishmaniasis: Differential diagnosis, diagnosis, histopathology, and management.J Am Acad Dermatol 73: 911-26; 927-8.